Clinical Research Details
Title:
Comparing Different Chemotherapy Regimens to Treat Breast Cancer Before Having Surgery
Purpose:
The purpose of this study is to compare different chemotherapy treatments and determine which is better for breast cancer patients.
Study Number:
202217102109
Number of Patients:
200
Elgibility:
Participants must be women with a histologically or pathologically confirmed diagnosis of Her-2/NEU negative inflammatory or locally advanced breast carcinoma. Participants must not have had prior chemotherapy, radiation therapy or biologic therapy for invasive breast cancer within the past five years.
Treatment:
Participants will be assigned to one of three treatment groups.
Group 1 will receive bevacizumab every two weeks with abraxane weekly for 12 weeks. Then they will receive doxorubicin, cyclophosphamide and pegfilgastrim every two weeks for 12 weeks total.
Group 2 will receive abraxane every week for 12 weeks. Then they will receive doxorubicin, cyclophosphamide and pegfilgastrim every two weeks for 12 weeks.
Group 3 will receive doxorubicin, cyclophosphamide and pegfilgastrim every two weeks for 12 weeks. Then they will receive abraxane every week for 12 weeks.
Three to six weeks after chemotherapy treatment is completed, all participants (Groups 1, 2, 3) will have surgery to remove any remaining breast cancer tumor.
Principal Investigator:
Enrollment Phone:
(708) 327-2237